68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 9/26/2018 |
| Start Date: | September 2015 |
| End Date: | September 2019 |
| Contact: | Herbert Vargas Alvarez, MD |
| Phone: | 646-888-5410 |
A Phase II Study of 68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer
The purpose of this study is to see if a new diagnostic research agent named 68Ga-RM2 can
show prostate cancer on a PET/CT scan. 68Ga-RM2 stands for Galium-68 labeled
DOTA-4-amino-1-carboxymethylpiperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2. This study
is being done because there are unmet medical needs to improve the current ways of detecting
prostate cancers before surgery.
show prostate cancer on a PET/CT scan. 68Ga-RM2 stands for Galium-68 labeled
DOTA-4-amino-1-carboxymethylpiperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2. This study
is being done because there are unmet medical needs to improve the current ways of detecting
prostate cancers before surgery.
Inclusion Criteria:
- Age ≥18 years
- Biopsy proven adenocarcinoma of the prostate
- Patients with low-risk, intermediate-risk and high-risk tumors according to NCCN
guidelines (2.2014) will be included
- Planned radical prostatectomy at MSKCC
- Multiparametric MRI of the pelvis (performed or planned) as routine care
Exclusion Criteria:
- Patients meeting any of the following exclusion criteria will not be eligible for
study entry:
- Hematologic
- Platelets <75K/mcL
- ANC <1.0 K/mcL
- Hepatic laboratory values
- Bilirubin >2.0 x ULN (institutional upper limits of normal)
- AST/ALT >2.5 x ULN
- Renal laboratory values
o Creatinine > 2.0 x ULN
- Claustrophobia interfering with MRI and PET/CT imaging
- Prior pelvic radiation
- Prior androgen deprivation therapy
- Patients deemed not surgical candidates due to prohibitive co-morbidities
We found this trial at
1
site
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Principal Investigator: Herbert Vargas Alvarez, MD
Phone: 646-888-5410
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
